Startle Testing with MDMA: FDA Clears Study to Proceed

On November 30, 2016, the FDA cleared the upcoming MAPS-sponsored Phase 1 study on the effect of MDMA on startle testing in healthy volunteers. Principal Investigator Barbara Rothbaum, Ph.D., a leading PTSD researcher, will conduct the study at Emory University in Atlanta, Georgia. The original protocol was approved by the Institutional Review Board (IRB) on July 26, 2016. The DEA is currently reviewing the protocol, with the study expected to begin in 2017.